Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life.

Scott IC, Ibrahim F, Panayi G, Cope AP, Garrood T, Vincent A, Scott DL, Kirkham B; TITRATE Programme Investigators.

Semin Arthritis Rheum. 2018 Dec 28. pii: S0049-0172(18)30536-5. doi: 10.1016/j.semarthrit.2018.12.006. [Epub ahead of print]

PMID:
30685064
2.

Cost-effectiveness of combination disease-modifying antirheumatics vs. tumour necrosis factor inhibitors in active rheumatoid arthritis: TACIT trial.

Patel A, Heslin M, Scott DL, Stringer D, Birrell F, Ibrahim F.

Arthritis Care Res (Hoboken). 2019 Jan 10. doi: 10.1002/acr.23830. [Epub ahead of print]

PMID:
30629813
3.

Intensive therapy and remissions in rheumatoid arthritis: a systematic review.

Hughes CD, Scott DL, Ibrahim F; TITRATE Programme Investigators.

BMC Musculoskelet Disord. 2018 Oct 30;19(1):389. doi: 10.1186/s12891-018-2302-5.

4.

Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.

Bechman K, Tweehuysen L, Garrood T, Scott DL, Cope AP, Galloway JB, Ma MHY.

J Rheumatol. 2018 Nov;45(11):1515-1521. doi: 10.3899/jrheum.171375. Epub 2018 Sep 1.

PMID:
30173149
5.

Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A, Stevenson M.

Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7. Review.

PMID:
29882210
6.
7.

Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Uttley L, Bermejo I, Ren S, Martyn-St James M, Wong R, Scott DL, Young A, Stevenson M.

Pharmacoeconomics. 2018 Sep;36(9):1063-1072. doi: 10.1007/s40273-018-0639-0. Review.

PMID:
29546668
8.

Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Ren S, Bermejo I, Simpson E, Wong R, Scott DL, Young A, Stevenson M.

Pharmacoeconomics. 2018 Jul;36(7):769-778. doi: 10.1007/s40273-018-0616-7. Review.

9.

Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?

Scott IC, Hider SL, Scott DL.

Drug Saf. 2018 Jul;41(7):645-653. doi: 10.1007/s40264-018-0651-5. Review.

PMID:
29500799
10.

Anthropogenic deposition of heavy metals and phosphorus may reduce biological N2 fixation in boreal forest mosses.

Scott DL, Bradley RL, Bellenger JP, Houle D, Gundale MJ, Rousk K, DeLuca TH.

Sci Total Environ. 2018 Jul 15;630:203-210. doi: 10.1016/j.scitotenv.2018.02.192. Epub 2018 Feb 22.

PMID:
29477819
11.

Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial.

Kingsbury SR, Tharmanathan P, Keding A, Ronaldson SJ, Grainger A, Wakefield RJ, Arundel C, Birrell F, Doherty M, Vincent T, Watt FE, Dziedzic K, O'Neill TW, Arden NK, Scott DL, Dickson J, Garrood T, Green M, Menon A, Sheeran T, Torgerson D, Conaghan PG.

Ann Intern Med. 2018 Mar 20;168(6):385-395. doi: 10.7326/M17-1430. Epub 2018 Feb 20.

12.

Impact of center volume and the adoption of laparoscopic donor nephrectomy on outcomes in pediatric kidney transplantation.

Burg JM, Scott DL, Roayaie K, Maynard E, Barry JM, Enestvedt CK.

Pediatr Transplant. 2018 May;22(3):e13121. doi: 10.1111/petr.13121. Epub 2018 Feb 2.

PMID:
29392867
13.

Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial.

Martin NH, Ibrahim F, Tom B, Galloway J, Wailoo A, Tosh J, Lempp H, Prothero L, Georgopoulou S, Sturt J, Scott DL; TITRATE Programme Investigators.

Trials. 2017 Dec 8;18(1):591. doi: 10.1186/s13063-017-2330-8.

14.

The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis.

Wailoo A, Hock ES, Stevenson M, Martyn-St James M, Rawdin A, Simpson E, Wong R, Dracup N, Scott DL, Young A.

Health Technol Assess. 2017 Nov;21(71):1-258. doi: 10.3310/hta21710. Review.

15.

Variable impacts of different remission states on health-related quality of life in rheumatoid arthritis.

Ma MHY, Ibrahim F, Kingsley GH, Cope A, Scott DL.

Clin Exp Rheumatol. 2018 Mar-Apr;36(2):203-209. Epub 2017 Oct 23.

PMID:
29148413
16.

Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?

Ibrahim F, Lorente-Cánovas B, Doré CJ, Bosworth A, Ma MH, Galloway JB, Cope AP, Pande I, Walker D, Scott DL.

Rheumatology (Oxford). 2017 Nov 1;56(11):2004-2014. doi: 10.1093/rheumatology/kex315.

17.

Participants' experiences of an Education, self-management and upper extremity eXercise Training for people with Rheumatoid Arthritis programme (EXTRA).

Bearne LM, Manning VL, Choy E, Scott DL, Hurley MV.

Physiotherapy. 2017 Dec;103(4):430-438. doi: 10.1016/j.physio.2016.12.002. Epub 2016 Dec 21.

PMID:
28823567
18.

Preventing Episodic Migraine With Caloric Vestibular Stimulation: A Randomized Controlled Trial.

Wilkinson D, Ade KK, Rogers LL, Attix DK, Kuchibhatla M, Slade MD, Smith LL, Poynter KP, Laskowitz DT, Freeman MC, Hoffer ME, Saper JR, Scott DL, Sakel M, Calhoun AH, Black RD.

Headache. 2017 Jul;57(7):1065-1087. doi: 10.1111/head.13120. Epub 2017 Jun 27.

PMID:
28656612
19.

Treating active rheumatoid arthritis with Janus kinase inhibitors.

Scott DL, Stevenson MD.

Lancet. 2017 Jul 29;390(10093):431-432. doi: 10.1016/S0140-6736(17)31659-8. Epub 2017 Jun 16. No abstract available.

20.

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Bermejo I, Stevenson M, Archer R, Stevens JW, Goka E, Clowes M, Scott DL, Young A.

Pharmacoeconomics. 2017 Nov;35(11):1141-1151. doi: 10.1007/s40273-017-0521-5. Review.

21.

Predicting responses in patients with rheumatoid arthritis to disease-modifying agents using baseline clinical data.

Gullick NJ, Mian AN, Ibrahim F, Walker D, Hassell A, Kiely PDW, Walsh DA, Young A, Scott DL; TITRATE Programme Investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):810-815. Epub 2017 May 8.

PMID:
28516868
22.

The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.

Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, Archer RJ, Simpson EL, Hock ES, Young A, Scott DL.

J Rheumatol. 2017 Jul;44(7):973-980. doi: 10.3899/jrheum.160941. Epub 2017 Feb 15. Review.

23.

Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis.

Scott IC, Ibrahim F, Lewis CM, Scott DL, Strand V.

RMD Open. 2016 Aug 26;2(2):e000270. doi: 10.1136/rmdopen-2016-000270. eCollection 2016.

24.

Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments.

Scott DL.

F1000Res. 2016 Aug 17;5. pii: F1000 Faculty Rev-2019. doi: 10.12688/f1000research.8812.1. eCollection 2016. Review.

25.

Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?

Mian AN, Ibrahim F, Scott DL, Galloway J; TITRATE study group.

Arthritis Res Ther. 2016 Jun 16;18(1):142. doi: 10.1186/s13075-016-1028-8.

26.

Beyond methotrexate monotherapy for early rheumatoid arthritis.

Scott DL.

Lancet. 2016 Jul 23;388(10042):309-310. doi: 10.1016/S0140-6736(16)30678-X. Epub 2016 Jun 7. No abstract available.

PMID:
27287831
27.

A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.

Ibrahim F, Tom BD, Scott DL, Prevost AT.

Trials. 2016 Jun 2;17(1):272. doi: 10.1186/s13063-016-1402-5. Review.

28.

Teardrop fracture following head-first impact in an ice hockey player: Case report and analysis of injury mechanisms.

Yue JJ, Ivancic PC, Scott DL.

Int J Spine Surg. 2016 Feb 3;10:9. doi: 10.14444/3009. eCollection 2016.

29.

Have radiographic progression rates in early rheumatoid arthritis changed? A systematic review and meta-analysis of long-term cohorts.

Carpenter L, Nikiphorou E, Sharpe R, Norton S, Rennie K, Bunn F, Scott DL, Dixey J, Young A.

Rheumatology (Oxford). 2016 Mar 8. pii: kew004. [Epub ahead of print]

PMID:
26961746
30.

A randomised trial evaluating anakinra in early active rheumatoid arthritis.

Scott IC, Ibrahim F, Simpson G, Kowalczyk A, White-Alao B, Hassell A, Plant M, Richards S, Walker D, Scott DL.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1):88-93. Epub 2016 Feb 2.

PMID:
26842950
31.

Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies.

Mian AN, Ibrahim F, Scott IC, Bahadur S, Filkova M, Pollard L, Steer S, Kingsley GH, Scott DL, Galloway J.

BMC Musculoskelet Disord. 2016 Jan 27;17:44. doi: 10.1186/s12891-016-0897-y.

32.

Cardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected data.

Grigoriou A, Ibrahim F, Chaabo K, Scott DL, Steer S, Galloway J.

Rheumatology (Oxford). 2016 Apr;55(4):763-4. doi: 10.1093/rheumatology/kev386. Epub 2015 Nov 24. No abstract available.

PMID:
26604333
33.

Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial.

Matcham F, Norton S, Scott DL, Steer S, Hotopf M.

Rheumatology (Oxford). 2016 Feb;55(2):268-78. doi: 10.1093/rheumatology/kev306. Epub 2015 Sep 8.

34.

Psychometric properties of a new treatment expectation scale in rheumatoid arthritis: an application of item response theory.

Ibrahim F, Ayis S, Hofmann D, Rose D, Wykes T, Cope A, Scott DL, Lempp H.

BMC Musculoskelet Disord. 2015 Sep 4;16:239. doi: 10.1186/s12891-015-0690-3.

35.

Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review.

Kingsley GH, Scott DL.

Psoriasis (Auckl). 2015 May 12;5:71-81. doi: 10.2147/PTT.S52893. eCollection 2015. Review.

36.

Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial.

Kingsbury SR, Tharmanathan P, Arden NK, Batley M, Birrell F, Cocks K, Doherty M, Edwards CJ, Garrood T, Grainger AJ, Green M, Hewitt C, Hughes R, Moots R, O'Neill TW, Roddy E, Scott DL, Watt FE, Torgerson DJ, Conaghan PG.

Trials. 2015 Mar 4;16:77. doi: 10.1186/s13063-015-0602-8.

37.

Improving medication adherence in rheumatoid arthritis (RA): a pilot study.

Ferguson A, Ibrahim FA, Thomas V, Weinman J, Simpson C, Cope AP, Scott DL, Lempp H.

Psychol Health Med. 2015;20(7):781-9. doi: 10.1080/13548506.2015.1009917. Epub 2015 Mar 16.

PMID:
25774559
38.

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.

Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, Birrell F, Chakravarty K, Maddison P, Heslin M, Patel A, Kingsley GH.

BMJ. 2015 Mar 13;350:h1046. doi: 10.1136/bmj.h1046.

39.

Calprotectin as a biomarker for rheumatoid arthritis: a systematic review.

Abildtrup M, Kingsley GH, Scott DL.

J Rheumatol. 2015 May;42(5):760-70. doi: 10.3899/jrheum.140628. Epub 2015 Mar 1. Review.

PMID:
25729036
40.
41.

Treat to target in managing inflammatory arthritis.

Mian A, Scott DL.

Br J Hosp Med (Lond). 2015 Jan;76(1):31-4. doi: 10.12968/hmed.2015.76.1.31.

PMID:
25585181
42.

Delivering future clinical trials in rheumatology.

Galloway JB, Scott DL.

J Rheumatol. 2015 Jan;42(1):18-20. doi: 10.3899/jrheum.141270. No abstract available.

PMID:
25554806
43.

Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.

Ibrahim F, Choy E, Gordon P, Doré CJ, Hakim A, Kitas G, Isenberg D, Griffiths B, Lecky B, Chakravarty K, Winer J, Danko K, Cooper RG, White-Alao B, Scott DL.

Rheumatology (Oxford). 2015 Jun;54(6):1050-5. doi: 10.1093/rheumatology/keu442. Epub 2014 Nov 27.

44.

Joint counts in inflammatory arthritis.

Scott IC, Scott DL.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-7-12. Epub 2014 Oct 30. Review.

PMID:
25365082
45.

Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.

Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Ma M, Walker D, Heslin M, Patel A, Kingsley G.

Health Technol Assess. 2014 Oct;18(66):i-xxiv, 1-164. doi: 10.3310/hta18660.

46.

Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.

Manning VL, Kaambwa B, Ratcliffe J, Scott DL, Choy E, Hurley MV, Bearne LM.

Rheumatology (Oxford). 2015 Feb;54(2):302-9. doi: 10.1093/rheumatology/keu319. Epub 2014 Aug 29.

PMID:
25173349
47.

The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis.

Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, Scott DL, Steer S.

Semin Arthritis Rheum. 2014 Oct;44(2):123-30. doi: 10.1016/j.semarthrit.2014.05.001. Epub 2014 May 29. Review.

48.

Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen.

Ma MH, Scott IC, Dahanayake C, Cope AP, Scott DL.

J Rheumatol. 2014 Jul;41(7):1298-303. doi: 10.3899/jrheum.131401.

PMID:
24931951
49.

Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.

Norton S, Fu B, Scott DL, Deighton C, Symmons DP, Wailoo AJ, Tosh J, Lunt M, Davies R, Young A, Verstappen SM.

Semin Arthritis Rheum. 2014 Oct;44(2):131-44. doi: 10.1016/j.semarthrit.2014.05.003. Epub 2014 May 9. Review.

50.

Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.

Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE.

Liver Transpl. 2014 Sep;20(9):1045-56. doi: 10.1002/lt.23917. Epub 2014 Aug 4.

Supplemental Content

Loading ...
Support Center